ESOPMay 15, 2026, 04:01 PM
Acrivon Grants 111,150 Stock Options to New Employee
AI Summary
Acrivon Therapeutics, Inc. announced the approval of an equity award to one employee under its 2023 Inducement Plan. The award consists of options to purchase 111,150 shares of common stock, granted on May 15, 2026, with an exercise price equal to the closing price on the grant date. These options will vest over time, subject to continued employment, and were approved by the Board as a material inducement for employment.
Key Highlights
- Approved equity award under 2023 Inducement Plan to one employee.
- Granted options to purchase 111,150 shares of common stock.
- Grant date for stock options was May 15, 2026.
- Exercise price equals closing price on Nasdaq on grant date.
- Options vest 25% on first anniversary, then 2.083% monthly.
- Award approved by Board as material inducement for employment.
Price Impact
More from ACRV